Altered expression patterns of syndecan-1 and -2 predict biochemical recurrence in prostate cancer.
about
Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicineOverexpression of transglutaminase 4 and prostate cancer progression: a potential predictor of less favourable outcomes.Prostate cancer cells specifically reorganize epithelial cell-fibroblast communication through proteoglycan and junction pathways.Increased SNAIL expression and low syndecan levels are associated with high Gleason grade in prostate cancerProteoglycan expression in normal human prostate tissue and prostate cancer.Tenascin-C, GLUT-1, and syndecan-2 expression in juvenile nasopharyngeal angiofibroma: correlations to vessel density and tumor stage.A subset of high Gleason grade prostate carcinomas contain a large burden of prostate cancer syndecan-1 positive stromal cells.
P2860
Q26796247-5FDB1B05-439F-4548-A2D4-ACB28B7594E8Q37370501-ACF2C13E-3937-49F7-8379-C53A836112EDQ38775596-D55DF7F8-A525-4E7B-BD3F-79EAE1035074Q39034367-CC4B0852-AF06-4974-8E7C-56B4033A884BQ40713205-B2359128-5F9E-4FDD-BD92-EBF3B9E5091CQ46314271-09D01C2F-877E-484B-B8B1-E8EC9BE25084Q48026733-FD5A69D3-C6CB-4C7E-BDE1-063140657D65
P2860
Altered expression patterns of syndecan-1 and -2 predict biochemical recurrence in prostate cancer.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Altered expression patterns of ...... recurrence in prostate cancer.
@en
Altered expression patterns of ...... recurrence in prostate cancer.
@nl
type
label
Altered expression patterns of ...... recurrence in prostate cancer.
@en
Altered expression patterns of ...... recurrence in prostate cancer.
@nl
prefLabel
Altered expression patterns of ...... recurrence in prostate cancer.
@en
Altered expression patterns of ...... recurrence in prostate cancer.
@nl
P2093
P2860
P356
P1476
Altered expression patterns of ...... recurrence in prostate cancer
@en
P2093
Enrique A Castellon
Enrique Ossandon
Federico Cifuentes
Héctor R Contreras
Juan Fullá
Rodrigo Ledezma
P2860
P304
P356
10.1038/AJA.2010.143
P577
2011-02-14T00:00:00Z